|
EP2311480B1
(en)
*
|
2002-09-20 |
2013-06-26 |
The Trustees of The University of Pennsylvania |
Compstatin analogs with improved activity
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
EP1960422B1
(en)
|
2005-11-28 |
2012-05-30 |
The Trustees of The University of Pennsylvania |
Potent compstatin analogs
|
|
US8637325B2
(en)
*
|
2009-02-16 |
2014-01-28 |
University Of Wyoming |
Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
|
|
WO2008048675A2
(en)
*
|
2006-10-20 |
2008-04-24 |
Celldex Therapeutics, Inc. |
Treatment for age-related macular degeneration and other diseases of the eye
|
|
EP2148691B1
(en)
*
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
JP2009003429A
(ja)
*
|
2007-05-18 |
2009-01-08 |
Panasonic Corp |
アクチュエータ
|
|
WO2008153963A1
(en)
*
|
2007-06-08 |
2008-12-18 |
The Trustees Of The University Of Pennsylvania |
Structure of compstatin-c3 complex and use for rational drug design
|
|
US8563259B2
(en)
|
2007-06-29 |
2013-10-22 |
The Trustees Of The University Of Pennsylvania |
Complement-mediated thrombophilic assay
|
|
MX2010003630A
(es)
*
|
2007-10-02 |
2010-04-21 |
Potentia Pharmaceuticals Inc |
Administracion sostenida de analogos de compstatina desde geles.
|
|
US20110190221A1
(en)
*
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
CA2738930C
(en)
*
|
2008-09-30 |
2021-08-17 |
The Trustees Of The University Of Pennsylvania |
Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
|
|
ES2655389T3
(es)
*
|
2009-05-01 |
2018-02-19 |
The Trustees Of The University Of Pennsylvania |
Compstatina modificada con esqueleto peptídico y modificaciones c-terminales
|
|
US20110104154A1
(en)
|
2009-10-30 |
2011-05-05 |
Alcon Research, Ltd. |
Single nucleotide polymorphisms and genes associated with age-related macular degeneration
|
|
WO2011106635A1
(en)
|
2010-02-25 |
2011-09-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of sepsis using complement inhibitors
|
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
CA2813049A1
(en)
|
2010-09-23 |
2012-03-29 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with improved stability and binding properties
|
|
EP3028720A1
(en)
*
|
2010-09-28 |
2016-06-08 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action
|
|
WO2012095519A1
(en)
|
2011-01-13 |
2012-07-19 |
Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie |
Potent inhibitors of complement activation
|
|
WO2012135624A1
(en)
|
2011-04-01 |
2012-10-04 |
The Trustees Of The University Of Pennsylvania |
Treatment of colon cancer using complement inhibitors
|
|
CN107050422B
(zh)
|
2011-05-11 |
2021-11-09 |
阿佩利斯制药公司 |
细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
|
|
WO2012162215A1
(en)
|
2011-05-20 |
2012-11-29 |
The Trustees Of The University Of Pennsylvania |
Promotion of fracture healing using complement inhibitors
|
|
WO2012174055A1
(en)
|
2011-06-13 |
2012-12-20 |
The Trustees Of The University Of Pennsylvania |
Wound healing using complement inhibitors
|
|
CN103796667A
(zh)
|
2011-06-22 |
2014-05-14 |
艾普莱斯制药公司 |
用补体抑制剂治疗慢性障碍的方法
|
|
PL2753636T3
(pl)
|
2011-09-07 |
2020-05-18 |
The Trustees Of The University Of Pennsylvania |
Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
|
|
US20160067357A1
(en)
*
|
2012-08-17 |
2016-03-10 |
Apellis Pharmaceuticals, Inc. |
Detection of high risk drusen
|
|
CA2891673C
(en)
*
|
2012-11-15 |
2025-10-07 |
Apellis Pharmaceuticals Inc |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
WO2014078734A2
(en)
*
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
WO2014100407A1
(en)
*
|
2012-12-19 |
2014-06-26 |
The Regents Of The University Of California |
Compstatin analogs
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
KR102344559B1
(ko)
|
2013-12-12 |
2021-12-31 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법
|
|
US10213476B2
(en)
|
2014-03-17 |
2019-02-26 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved potency and pharmacokinetic properties
|
|
MX2017005454A
(es)
|
2014-12-23 |
2017-07-04 |
Multi Chem Group Llc |
Agentes depuradores de azufre a base de acrilato para usarse en actividades en pozos petroleros.
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
EP3340983B1
(en)
|
2015-08-26 |
2023-10-04 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
JP6968787B2
(ja)
|
2015-10-07 |
2021-11-17 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. |
投与レジメン
|
|
BR112019007613A2
(pt)
|
2016-10-17 |
2019-07-02 |
Apellis Pharmaceuticals Inc |
terapia de combinação para inibição de c3
|
|
CN110603252A
(zh)
|
2017-03-01 |
2019-12-20 |
艾其林医药公司 |
用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
US11040107B2
(en)
|
2017-04-07 |
2021-06-22 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
EP3661493A4
(en)
|
2017-08-02 |
2021-04-14 |
Achillion Pharmaceuticals, Inc. |
TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
|
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
KR20240167712A
(ko)
|
2017-12-15 |
2024-11-27 |
아펠리스 파마슈티컬스 인코포레이티드 |
투여 요법 및 관련 조성물 및 방법
|
|
AU2019228639A1
(en)
*
|
2018-02-27 |
2020-09-17 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
|
HUE057693T2
(hu)
*
|
2018-04-06 |
2022-05-28 |
Univ Pennsylvania |
Fokozott oldhatóságú és javított farmakokinetikai tulajdonságú kompsztatin analógok
|
|
US11814391B2
(en)
|
2018-09-06 |
2023-11-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
|
MX2021002640A
(es)
|
2018-09-06 |
2021-07-16 |
Achillion Pharmaceuticals Inc |
Formas morficas de los inhibidores del factor d del complemento.
|
|
EP3856164B1
(en)
|
2018-09-25 |
2024-08-07 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
US12239645B2
(en)
|
2018-12-17 |
2025-03-04 |
Achillion Pharmaceuticals, Inc. |
Targeted dosing for the treatment of complement mediated disorders
|
|
JP7635138B2
(ja)
|
2019-03-22 |
2025-02-25 |
アキリオン ファーマシューティカルズ， インコーポレーテッド |
補体媒介性障害の治療のための医薬化合物
|
|
US11510939B1
(en)
|
2019-04-19 |
2022-11-29 |
Apellis Pharmaceuticals, Inc. |
RNAs for complement inhibition
|
|
BR112022003760A2
(pt)
|
2019-08-27 |
2022-05-31 |
Zp Spv 3 K/S |
Análogos de compstatina e seus usos médicos
|
|
JP7676377B2
(ja)
|
2019-10-22 |
2025-05-14 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
補体成分Ｃ３ ｉＲＮＡ組成物およびその使用方法
|
|
US20250197403A1
(en)
|
2020-02-20 |
2025-06-19 |
Achillion Pharmaceuticals, Inc. |
Heteroaryl compounds for treatment of complement factor d mediated disorders
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
KR20230017789A
(ko)
|
2020-04-30 |
2023-02-06 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
|
|
BR112022022980A2
(pt)
|
2020-05-12 |
2022-12-20 |
Alexion Pharma Inc |
Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
|
|
CA3185730A1
(en)
|
2020-07-16 |
2022-01-20 |
Anne Pernille Tofteng SHELTON |
Inhibitors of complement factor c3 and their medical uses
|
|
CN116437913A
(zh)
|
2020-09-23 |
2023-07-14 |
艾其林医药公司 |
用于治疗补体介导的病症的药物化合物
|
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
|
|
EP4423273A1
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
CN114605495A
(zh)
*
|
2022-04-20 |
2022-06-10 |
广州市乾相生物科技有限公司 |
一种乳四肽的合成方法
|
|
WO2025176843A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
|
|
WO2025229200A1
(en)
|
2024-05-03 |
2025-11-06 |
Bachem Holding Ag |
Manufacture of disulfide bonded peptides
|
|
CN119176856B
(zh)
*
|
2024-11-22 |
2025-03-18 |
杭州诺泰诺和生物医药科技有限公司 |
Pegcetacoplan的制备方法
|